Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...
manilatimes44m
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
Milestone's NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...